Category: Enzyvant

Enzyvant Announces Collaboration with PerkinElmer to Enable Diagnostic Testing for Farber Disease

BASEL, Switzerland and WALTHAM, Mass., July 19, 2018 /PRNewswire/ — Enzyvant, a biopharmaceutical company focused on developing innovative treatments for people living with rare diseases, today announced that it has formed a collaboration with PerkinElmer Genomics, a global genomic testing company. PerkinElmer Genomics will leverage its network of global labs and testing platform to offer…

Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly

Rolling BLA submission has been agreed to by FDA and is intended to expedite the Agency’s review process Completion of rolling BLA submission anticipated by end of 2018 RVT-802 has been awarded Breakthrough Therapy and RMAT designations, as well as pediatric rare disease and orphan designations Enzyvant to present at Roivant Pipeline Day on July…

Enzyvant Expands Executive Leadership Team with Appointments of Alan Kimura as Chief Medical Officer and Tamara Joseph as General Counsel

BASEL, Switzerland, June 4, 2018 /PRNewswire/ — Enzyvant, a biopharmaceutical company focused on developing innovative therapies for patients with rare diseases, today announced the appointments of Alan Kimura, MD, PhD as Chief Medical Officer and Tamara Joseph, JD, LLM as General Counsel. “Alan and Tamara are accomplished executives, and I am excited to welcome them…

Enzyvant Launches Re:GenerationHope Initiative in Honor of Rare Disease Day 2018

Re:GenerationHope raises awareness and funds for the complete DiGeorge Anomaly and primary immunodeficiency communities The congenital athymia associated with complete DiGeorge Anomaly results in severe primary immunodeficiency and is almost uniformly fatal if untreated BASEL, Switzerland, Feb. 28, 2018 /PRNewswire/ — Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases,…

Enzyvant Initiates Farber Disease Natural History Study

Global study aims to define the natural course of Farber disease and the relationship between specific symptoms, biomarkers, and prognosis Enzyvant anticipates initiating clinical trial of RVT-801 for Farber disease in 2018 BASEL, Switzerland, October 16, 2017 / PRNewswire / — Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases,…

Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802

– RVT-802 is an investigational tissue-based therapy for primary immune deficiency associated with complete DiGeorge Syndrome – RVT-802 has also received Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and orphan drug designation from FDA – Enzyvant anticipates potential BLA filing in the first half of 2018 – Morgan Molloy to join Enzyvant as Chief…